Prosecution Insights
Last updated: November 11, 2026
Application No. 18/106,394

METHODS OF DETECTING TRICHOMONAS TENAX

Final Rejection §102§103§112
Filed
Feb 06, 2023
Priority
Feb 07, 2022 — provisional 63/307,513
Examiner
SWITZER, JULIET CAROLINE
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Adtalem Global Education Inc.
OA Round
2 (Final)
43%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allowance Rate
221 granted / 519 resolved
-17.4% vs TC avg
Strong +54% interview lift
Without
With
+53.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
51 currently pending
Career history
574
Total Applications
across all art units

Statute-Specific Performance

§101
20.3%
-19.7% vs TC avg
§103
22.4%
-17.6% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
32.0%
-8.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 519 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-16 in the reply filed on 12/16/25 is acknowledged. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 63/307513, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. Claims 1, 2, 3, 4, 6, 7, 9, 10 11, 12, 13, 14, 15, and 16 are sufficiently broad so as to encompass method of amplification that do not rely on LAMP isothermal amplification, whereas the provisional application only teaches LAMP isothermal amplification using primers comprising SEQ ID NO: 2-7. The broader scope in the instant claims is not disclosed in the provisional and so the effective filing date for these claims is the actual filing date of this application, namely 2/6/2023. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 1, 3, 4-5, 9, 11, 13 and 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is indefinite because it is not clear if an amplification product is required to be produced or not. The contacting step states that the primer pair hybridizes to SEQ ID NO: 1 “if present in the nucleic acid of the biological sample” and “if at least one amplification product is present” which clearly encompasses embodiments where no amplification product is present. However, the “thereby” clause in the contacting step states “generating…mixture comprising one or more amplification products,” which appears to require the products be present, which conflicts with the “if” statements in other portions of the claim. Claim 16 is indefinite because it is unclear what makes PCR conventional. As neither the conditions of the claimed amplification nor those of the “conventional PCR” are set forth it impossible to know the metes and bounds of the claim since the sensitivity of a method can vary depending on how the sample is prepared, the primers selected and the rection conditions. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 3, 4, and 9 are is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mallat (JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2004, p. 3886–3887). The reference teaches contacting nucleic acid obtained from a biological sample with at least one polynucleotide primer pair under amplification conditions, thereby generating an amplified nucleic acid mixture and analyzing the products, wherein under amplification conditions, the at least one primer pair hybridizes to SEQ ID NO: 1 , or to a subsequence of SEQ ID NO: 1, or a complement of a subsequence of SEQ ID NO: 1, if present in the nucleic acid of the biological sample, thereby generating an amplified nucleic acid mixture comprising one or more amplification products and analyzing the amplified mixture under conditions wherein if at least one amplification product is present then T. tenax is determined to be present in the biological sample. Namely, the reference teaches PCR amplification and then sequencing of a biological sample from a patient. The reference teaches that “the sequence of the amplified 368-bp fragment …exhibited 100% homology to Trichomonas tenax.” The reference does not teach detecting any other organism in the patient sample, therefore, the method meets the limitation “no nucleic acid of microbes/pathogens selected from one or more of T. vaginilas, S.pyogenes, S. aureus, E. coli, E. faecalis, and C. albicans is detected.” In the assay of the patient biological sample, none of these were detected. The reference teaches that forward primer was identical to 1-20 of SEQ ID NO: 1, and the reverse primer was the complement of nucleotide 349-368 of SEQ ID NO: 1. The amplicon amplified a portion of T. tenax when the T. tenax was in the sample, and this was confirmed by sequencing the amplicon (p. 3886, Col. 2). With regard to the limitation that the set of primers “comprises” LAMP primers, it is noted that the claim does not require that a complete set of LAMP primers or any required number of LAMP primer pairs is present, and so since any primer pair could be used as a LAMP primer when combined with appropriate FIP and BIP primers, the primer pair taught in the reference is construed as a LAMP primer pair. Since multiple copies of the primers are present, the method comprises a set of at least two primer pairs, albeit each primer pair is of the same sequence; Claim 4 does not require otherwise. Regarding claim 15, the primers do not share identity with E. coli and if E. coli were present, it would not be expected to be amplified. Claim(s) 1, 3, 4, 9, and 15 are is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Duboucher et al. (JOURNAL OF CLINICAL MICROBIOLOGY, Mar 2006, p. 1165-1168). The reference teaches contacting nucleic acid obtained from a biological sample with at least one polynucleotide primer pair under amplification conditions, thereby generating an amplified nucleic acid mixture and analyzing the products, wherein under amplification conditions, the at least one primer pair hybridizes to SEQ ID NO: 1 , or to a subsequence of SEQ ID NO: 1, or a complement of a subsequence of SEQ ID NO: 1, if present in the nucleic acid of the biological sample. Further, the reference teaches analyzing the amplified mixture. Attention is drawn to the “negative control” which is a BAL sample without trichomonads (p. 1165). In this assay, no amplification product was detected. Therefore, the “if at least one amplification product is present” is a negative result- no amplification product is present, and therefore T. tenax does not have to be present in the sample. Further, there is no reported detection of nucleic acid from any of the additional recited species in the claim. Therefore, claim 1 is anticipated. The reference teaches a nested PCR amplification wherein two different primer sets which hybridize to instant SEQ ID NO: 1 were utilized to attempt to amplify a target from the sample, which was then sequenced. The outer forward primer was identical to 1-20 of SEQ ID NO: 1, and the outer reverse primer was the complement of nucleotide 349-368 of SEQ ID NO: 1. See p. 1166 and Figure 2. The sample was a bronchoalveolar lavage specimen from a human that does not contain trichomonads (p. 1165, Col. 2). With regard to the limitation that the set of primers “comprises” LAMP primers, it is noted that the claim does not require that a complete set of LAMP primers or any required number of LAMP primer pairs is present, and so since any primer pair could be used as a LAMP primer when combined with appropriate FIP and BIP primers, the primer pairs taught in the reference are construed as a LAMP primer pairs. Regarding claim 15, the primers do not share identity with E. coli and if E. coli were present, it would not be expected to be amplified. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 3-10, 15 and 16 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mallat (JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2004, p. 3886–3887) in view of Reyes et al. (Diagnostic Microbiology and Infectious Disease 79 (2014) 337–341) and Duboucher (JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2006, p. 1165–1168). Mallet teaches that Trichomonas tenax caused a pulmonary infection in a 58-year old man (title). The reference teaches that amplification of the 5.8S rRNA sequence followed by sequencing is a way to identify species of Trichomonas in a sample (p. 5886, 2nd column). The 5.8S rRNA sequences present the advantages of being present in multiple copies in the genome and of being conserved in certain regions and variable in others, even between very closely related species (p. 3887). The additional teachings Mallet are given previously in this Office action and are fully incorporated here. Mallet does not teach detection T. tenax using LAMP isothermal amplification, or a complete set of LAMP primers. Reyes teaches using LAMP for the detection of Trichomonas vaginalis. The reference teaches that LAMP primers were designed using commercially available software, namely LAMP Designer version 1.02 (section 2.4). The reference teaches that the LAMP method demonstrated advantages over conventional PCR, including high efficiency, use of simple equipment, and its fast, ideal for rapid point-of-care tests. The DNA polymerase can tolerate PCR inhibitors found in many samples, and thus, only simple sample preparation is needed for amplification. The method is a rapid and cost-effective tool for detecting targets (section 4). Furthermore, Reyes teaches that the LAMP assay was 10-1000 times more sensitive than the conventional PCR performed. Furthermore, the complete sequence of the target amplified by Mallet was known and had been aligned with closely related species. See Duboucher et al., Figure 2, noting that the outer primers taught by the reference are identical to the primers taught by Mallet, and that the sequence given for T. tenax in Figure 2 is identical to instant SEQ ID NO: 1. It would have been prima facie obvious to have modified the method for detection taught by Mallet so as to have selected LAMP primers and carried out a LAMP amplification for the detection of T tenax from the sequence disclosed by Duboucher. One would have been motivated to do so (1) because Mallet teaches that the region is good for detection of T. tenax since it is 5.8S rRNA sequences present the advantages of being present in multiple copies in the genome and of being conserved in certain regions and variable in others, even between very closely related species, (2) Reyes teaches multiple advantages of using LAMP, including a much higher sensitivity than conventional PCR, (3) Duboucher provided the full length sequence of the 5.8S rRNA sequence for T. tenax and (4) Reyes teaches that there were commercially available primer selection tools for designing LAMP primers. Therefore, it would have been obvious to have selected primers from within the known 5.8S rRNA gene for the specific detection of T. tenax. Furthermore, regarding claims 5 and 8, which require SEQ ID NO: 2-7, each of these primers are identical to portions of or the complement of to the very short sequence taught in Figure 2 of Duboucher. The combined teachings of the cited references would have suggested a finite number of possible PCR primer pairs that could be designed from the known amplicon taught by Mallet to the ordinary artisan, and, based on the teachings of Reyes, the ordinary artisan would have expected predictable results in obtaining and using these oligonucleotides in a LAMP amplification reaction for the sensitive and specific detection of T. tenax. Thus, absent any evidence of unexpected results with respect to particular primers the method of claims 5 and 8 would have been prima facie obvious before the instant filing date in view of the combined teachings of the cited references. Claim(s) 11 and 12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mallet in view of Reyes and Duboucher, as applied to claims 1, 3-10, 15 and 16 above, and further in view of Jiang et al. International Journal of Infectious Diseases 107 (2021) 145–152. The teachings of Mallet in view of Reyes and Duboucher as they relate to claims 1, 4, and 6 are given previously in this Office action and are fully incorporated here. Reyes teaches the LAMP reaction was incubated at 60°C for 30-45minutes, with a MgSO4 concentration of 8mmol/L. Mallet in view of Reyes and Duboucher does not teach the conditions recited in claims 11 and 12. However, these were well known to be optimizable variables of a LAMP reaction. For example, Jiang taught optimization of a LAMP assay by testing performance at different reagent concentrations, including MgSO4, reaction times, and incubation temperatures (p. 148). The optimized LAMP assay taught by Jiang ran at 6mM MgSO4, at 65°C for 60 minutes. Generally, differences in concentration or temperature will not support the patentabilty of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. Here the prior art recognized time, temperature and reagent concentrations as variables which achieve a result of supporting LAMP amplification, and thus, it would have been obvious to determine optimum or workable ranges for a LAMP assay for the detection of T. tenax. One of ordinary skill in the art would have had a reasonable expectation of success to formulate the claimed combination of variables because the prior art demonstrates that these values are with ranges routinely tested for the development of LAMP assays. Claim(s) 13 and 14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mallet, as applied to claims 1, 3-10, 15 and 16 above, and further in view of Dybicz et al. (Cited in IDS 9/19/23). The teachings of Mallet in view of Reyes and Duboucher as they relate to claims 1, 4, and 6 are given previously in this Office action and are fully incorporated here. Mallet in view of Reyes and Duboucher does not teach detecting T. tenax in one of the samples listed in claims 13 and 14. Dybicz teaches that T. tenax is present in the human oral cavity and teaches obtaining oral washes (which include saliva) for the detection of T. tenax in samples by PCR. It would have been prima facie obvious to have modified the method taught by Mallet so as to have detected T. tenax in oral washing samples in order to provide an alternative method for detecting T. tenax in patients, particularly as a way to survey the oral health of patients. Response to Remarks Any rejection which is not specifically addressed or reiterated is withdrawn in view of amendment to the claims. The declaration filed with the response has been considered and is persuasive to overcome the 102 rejection over Matthew et al. Applicant argues that claim 16 is definite because it is clear that LAMP is compared to “conventional PCR.” However, there is no meaning or definition for what makes a PCR “conventional” so the basis for the comparison remains unclear. The rejection over Mallat is updated. Applicant argues that “Mallat does not disclose amplifying nucleic acid from a biological sample under conditions wherein T. tenax is detected if present in the biological sample and no nucleic acid of microbes/pathogens selected from one or more of T. vaginalis, S. pyogenes, S. aureus, E. coli, E. faecalis, and C. albicans is detected.” Mallat teaches amplification and does not report detection of any of these in the patient sample (i.e. the bronchoalveolar fluid assayed to identify the species), therefore no nucleic acid of any of these is detected in the sample from the patient. This meets the claim limitations. Applicant points out that in addition to the patient sample, Mallat also amplified nucleic acids from a vaginal sample. This is a different embodiment than the one applied against the claims. The claims do not exclude the amplification that Mallat conducted on the patient sample which meets all claim limitations. Applicant argues that Duboucher does not disclose any method that specifically detects T. tenax, and this is a feature that is not required by the claims in the instance where no amplification product is observed, as in the negative control assay taught by the reference. Regarding obviousness, the response points out that Mallat teaches detecting T. tenax in the respiratory tract where it is the predominant Trichomonad species. Nonetheless, Mallat specifically states that they carried out the amplification and sequencing “in order to identify the species of Trichomonas” which is a clear suggestion that a method to identify the species present in a sample is desirable (See p. 3886, 2nd column, first full ¶). Furthermore, Duboucher evidences that other species of Trichomonas are sometimes present in respiratory tract samples. Applicant argues that there is no teaching, suggestion, or motivation in Mallat to adapt its methods to specifically detect T. tenax without detecting other coexisting microbes and pathogens. Again, this is a feature not claimed. There is no requirement in the claim for the other mentioned pathogens to be coexisting, and most claims are generic to any “biological” sample. Applicant argues that Reyes does not provide guidance how to develop a LAMP assay for T. tenax but Reyes does specifically teach how to develop such an assay for a closely related target, as discussed in the rejection. The fact that Reyes does not provide guidance for T. tenax is a piecemeal analysis. The rejections are maintained. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet Switzer whose telephone number is (571)272-0753. The examiner can normally be reached Monday to Thursday, 8:00 AM-3:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Winston Shen can be reached at (571)-272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Juliet Switzer Primary Examiner Art Unit 1682 /JULIET C SWITZER/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Feb 06, 2023
Application Filed
Feb 11, 2026
Non-Final Rejection mailed — §102, §103, §112
Jun 11, 2026
Response Filed
Aug 28, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766131
COMPOSTIONS AND METHODS FOR TREATING PROSTATE CANCER
3y 3m to grant Granted Oct 20, 2026
Patent 12760376
DNAZYME FOR CLOSTRIDIUM DIFFICILE DETECTION
2y 5m to grant Granted Oct 13, 2026
Patent 12747479
COMPOSITIONS AND METHODS FOR DETECTION OF MALARIA
3y 4m to grant Granted Sep 29, 2026
Patent 12729403
MYH11/NDE1 REGION AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF ENDOTHELIAL PROGENITOR CELLS (EPCS)
3y 10m to grant Granted Sep 08, 2026
Patent 12729406
NOVEL OLIGONUCLEOTIDES FOR DETECTING STAPHYLOCOCCUS
3y 8m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
43%
Grant Probability
96%
With Interview (+53.9%)
3y 8m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 519 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month